

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Mark Robert Southern, et al.

Application No: 10/559,157
(International Application No: PCT/US2004/021472)

Filed: (International Application: 02 July 2004 (02.07.2004))

For: DRUG CANDIDATE SELECTION BY HYDROGEN EXCHANGE
CHARACTERIZATION OF LIGAND-INDUCED RECEPTOR
CONFORMATION

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying Form PTO-1449, except for any US patents and published US patent applications which may be listed.

The Examiner is respectfully requested to review the items listed on the attached form and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate Form 1449, and return one copy to the undersigned.

This Statement should not be construed as a representation that the cited references are

CERTIFICATE OF MAILING

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of person mailing page:

Laura M. McNeely

Type or print name of person


Date: December 27, 2006

This Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist. This Statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

MARK ROBERT SOUTHERN, *et al.*

BY



DANIEL A. MONACO

Registration No. 30,480

DRINKER BIDDLE & REATH LLP

One Logan Square

18th and Cherry Streets

Philadelphia, PA 19103-6996

TEL: (215) 988-3312

FAX: (215) 988-2757

Attorney for Applicants

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 43072-0002US1	SERIAL NO. 10/559,157
	APPLICANT: Southern, Mark Robert et al.	
	FILING DATE July 2, 2004	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	US2002/0061539 A1	5/23/2002	Baxter, John D., et al.	435	7.1	
	AB	US2003/0032065 A1	2/13/2003	Hilser, Vince, et al.	435	7.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AC	Allan et al., "Induction of a Novel Conformation in the Progesterone Receptor by ZK299 Involves a Defined Region of the Carboxyl-Terminal Tail," <i>Mol. Endocrinol.</i> , 10(10): 1206-1213 (1996).
	AD	Berger et al., "Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein γ Selective Modulator," <i>Mol. Endocrinol.</i> , 17(4): 662-676 (2003).
	AE	Chen et al., "Folding of malate dehydrogenase inside the GroEL-GroES cavity," <i>Nature Struct. Bio.</i> , 8(8): 721 - 728 (2001)
	AF	Couette et al., "Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hereto-oligomeric structure," <i>Biochem. J.</i> , 315: 421-427 (1996).
	AG	Englander, et al., "Protein Structure change studied by hydrogen-deuterium exchange, functional labeling, and mass spectrometry," <i>PNAS</i> , 100(12): 7057-7062 (2003).
	AH	Exsar™, "Small Molecule Lead Discovery & Optimization," July 24, 2003 http://www.exsar.com/research_smallmolecule.shtml
	AI	Freire, "The propagation of binding interactions to remote sites in proteins: Analysis of the binding of the monoclonal antibody D1.3 to lysozyme," <i>Proc. Natl. Acad. Sci.</i> , 96: 10118-10122 (1999)
	AJ	Grazybowski, et al., "Combinatorial computational method gives new picomolar ligands for a known enzyme," <i>PNAS</i> , 99(3): 1270-1273 (2002)
	AK	Hamuro, et al., "Rapid Analysis of Protein Structure and Dynamics by Hydrogen/Deuterium Exchange Mass Spectrometry," <i>J. Biomol. Tech.</i> , 14(3): 171-182 (2003).
	AL	Jones, et al., "Principles of protein-protein interactions," <i>Proc. Natl. Acad. Sci.</i> , 93: 13-20 (1996).
	AM	Kenakin, "Inverse, protean, and ligand-selective agonism: matters of receptor conformation," <i>FASEB J.</i> , 15: 598-611 (2001).
	AN	McDonnell, et al., "Analysis of Estrogen Receptor Function <i>in Vitro</i> Reveals Three Distinct Classes of Antiestrogens," <i>Mol. Endocrinol.</i> , 9(6): 659-669 (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 43072-0002US1	SERIAL NO. 10/559,157
	APPLICANT: Southern, Mark Robert et al.	
	FILING DATE July 2, 2004	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AO	Olefsky et al., "PPAR γ and the Treatment of Insulin Resistance," <i>TEM</i> , 11(9): 362-367 (2000).
AP	Olefsky, "Treatment of insulin resistance with peroxisome proliferators-activated receptor γ agonists," <i>J. Clin. Invest.</i> , 106(4): 467-472 (2000).
AQ	Rarey, et al., "Docking of hydrophobic ligands with interaction-based matching algorithms," <i>Bioinformatics</i> , 15(3): 243-250 (1999).
AR	Schaaf et al., "Molecular Determinants of Glucocorticoid receptor Mobility in Living Cells: the Importance of Ligand Affinity," <i>Mol. Cell. Biol.</i> , 23(6): 1922-1934 (2003).
AS	Schnecke et al., "Virtual Screening with solvation and ligand-induced complementarity," <i>Perspect. Drug Discov.</i> , 20: 171-191 (2000).
AT	Wooll, et al., "Ensemble Modulation as an Origin of Denaturant-independent Hydrogen Exchange in Proteins," <i>J. Mol. Biol.</i> , 301: 247-256 (2000).
AU	Yan et al., "Dynamics and Ligand-Induced Solvent Accessibility Changes in Human Retinoid X Receptor Homodimer Determined by Hydrogen Deuterium Exchange and Mass Spectrometry," <i>Biochemistry</i> , 43: 909-917 (2004).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	